New Zealand Markets closed

Bio-Rad Laboratories, Inc. (BIO)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
480.29+12.77 (+2.73%)
At close: 04:04PM EDT
480.29 +0.71 (+0.15%)
After hours: 04:08PM EDT

Bio-Rad Laboratories, Inc.

1000 Alfred Nobel Drive
Hercules, CA 94547
United States
510 724 7000

IndustryMedical Devices
Full-time employees8,200

Key executives

NameTitlePayExercisedYear born
Mr. Norman D. SchwartzChairman, CEO & Pres3.15M26.13M1950
Mr. Ilan DaskalExec. VP & CFO1.18M782.98k1966
Dr. Andrew J. Last Ph.D.Exec. VP & COO1.54M1.03M1960
Mr. Michael CrowleyExec. VP of Global Commercial Operations974.94k1.85M1962
Ms. Dara Grantham WrightExec. VP & Pres of Clinical Diagnostics Group1.06MN/A1976
Mr. Ajit RamalingamSr. VP & Chief Accounting OfficerN/AN/A1973
Mr. Yong ChungVP of Investor RelationsN/AN/AN/A
Mr. Timothy S. ErnstExec. VP, Gen. Counsel & Sec.N/AN/A1960
Colleen CoreySr. VP of Global HRN/AN/AN/A
Lee BoydSr. VP of Global Commercial Operations - Asia PacificN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Corporate governance

Bio-Rad Laboratories, Inc.’s ISS governance QualityScore as of 1 February 2023 is 10. The pillar scores are Audit: 10; Board: 10; Shareholder rights: 10; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.